<HashMap><database>biostudies-literature</database><scores/><additional><submitter>BEAR-MOON Design Group</submitter><funding>NIAMS NIH HHS</funding><pagination>23259671211065447</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8793429</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>BEAR (bridge-enhanced anterior cruciate ligament [ACL] restoration), a paradigm-shifting technology to heal midsubstance ACL tears, has been demonstrated to be effective in a single-center 2:1 randomized controlled trial (RCT) versus hamstring ACL reconstruction. Widespread dissemination of BEAR into clinical practice should also be informed by a multicenter RCT to demonstrate exportability and compare efficacy with bone--patellar tendon-bone (BPTB) ACL reconstruction, another clinically standard treatment.&lt;h4>Purpose&lt;/h4>To present the design and initial preparation of a multicenter RCT of BEAR versus BPTB ACL reconstruction (the BEAR: Multicenter Orthopaedic Outcomes Network [BEAR-MOON] trial). Design and analytic issues in planning the complex BEAR-MOON trial, involvi</pubmed_abstract><journal>Orthopaedic journal of sports medicine</journal><pubmed_title>Design Features and Rationale of the BEAR-MOON (Bridge-Enhanced ACL Restoration Multicenter Orthopaedic Outcomes Network) Randomized Clinical Trial.</pubmed_title><pmcid>PMC8793429</pmcid><funding_grant_id>R01 AR074131</funding_grant_id><pubmed_authors>Beck GJ</pubmed_authors><pubmed_authors>BEAR-MOON Design Group</pubmed_authors><pubmed_authors>Winalski CS</pubmed_authors><pubmed_authors>Wright R</pubmed_authors><pubmed_authors>Yalcin S</pubmed_authors><pubmed_authors>Kaeding C</pubmed_authors><pubmed_authors>McErlean E</pubmed_authors><pubmed_authors>Spindler KP</pubmed_authors><pubmed_authors>Magnussen R</pubmed_authors><pubmed_authors>Kriz P</pubmed_authors><pubmed_authors>Owens BD</pubmed_authors><pubmed_authors>Strnad G</pubmed_authors><pubmed_authors>Melgaard C</pubmed_authors><pubmed_authors>Jones MH</pubmed_authors><pubmed_authors>Hulstyn MJ</pubmed_authors><pubmed_authors>Saluan P</pubmed_authors><pubmed_authors>Calbrese G</pubmed_authors><pubmed_authors>Fleming BC</pubmed_authors><pubmed_authors>Cox CL</pubmed_authors><pubmed_authors>Fitch R</pubmed_authors><pubmed_authors>Flanigan D</pubmed_authors><pubmed_authors>Imrey PB</pubmed_authors><pubmed_authors>Katz JN</pubmed_authors><pubmed_authors>Fadale PD</pubmed_authors><pubmed_authors>Farrow L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Design Features and Rationale of the BEAR-MOON (Bridge-Enhanced ACL Restoration Multicenter Orthopaedic Outcomes Network) Randomized Clinical Trial.</name><description>&lt;h4>Background&lt;/h4>BEAR (bridge-enhanced anterior cruciate ligament [ACL] restoration), a paradigm-shifting technology to heal midsubstance ACL tears, has been demonstrated to be effective in a single-center 2:1 randomized controlled trial (RCT) versus hamstring ACL reconstruction. Widespread dissemination of BEAR into clinical practice should also be informed by a multicenter RCT to demonstrate exportability and compare efficacy with bone--patellar tendon-bone (BPTB) ACL reconstruction, another clinically standard treatment.&lt;h4>Purpose&lt;/h4>To present the design and initial preparation of a multicenter RCT of BEAR versus BPTB ACL reconstruction (the BEAR: Multicenter Orthopaedic Outcomes Network [BEAR-MOON] trial). Design and analytic issues in planning the complex BEAR-MOON trial, involvi</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jan</publication><modification>2026-05-09T06:04:08.13Z</modification><creation>2022-02-11T15:39:48.564Z</creation></dates><accession>S-EPMC8793429</accession><cross_references><pubmed>35097143</pubmed><doi>10.1177/23259671211065447</doi></cross_references></HashMap>